All In Biotech

Drug Trial Radar · NCT01985334

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

A Prospective, Multicenter, 12-week, Randomized Open-label Study to Evaluate the Efficacy and Safety of Glycopyrronium (50 Micrograms o.d.) or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination (110/50 Micrograms o.d.) Regarding Symptoms and Health Status in Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD) Switching From Treatment With Any Standard COPD Regimen

Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 4,389 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,389

Actual

Start

Feb 14, 2014

Primary completion

Apr 29, 2016

Study completion Apr 29, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their current COPD therapy. This study aims to provide data on how non-exacerbating, but still symptomatic patients with moderate COPD switching from their current COPD treatment to glycopyrronium bromide or indacaterol maleate and glycopyrronium bromide FDC maintain or improve their symptoms. Another purpose of this study is to increase awareness and usage of validated COPD symptoms tools and dyspnea questionnaires in order to facilitate clinical assessment and improve early diagnosis of symptomatic patients.

Conditions

  • COPD

Interventions

  • GlycopyrroniumDrug

    Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day

  • SABADrug

    Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy

  • LABADrug

    Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

  • Indacaterol maleate and glycopyrronium bromideDrug

    Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day

  • LAMADrug

    Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy

  • SAMADrug

    Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy

  • ICSDrug

    Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)Time frame: Week 12 (Visit 4)
  2. Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Week 12 (Visit 4)
  3. Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDCTime frame: Week 12 (Visit 4)
  4. Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Week 12 (Visit 4)
  5. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)Time frame: Day 1 (baseline) and week 12
  6. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Day 1 (baseline) and week 12
  7. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDCTime frame: Day 1 (baseline) and week 12
  8. Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Day 1 (baseline) and week 12

Locations

542 sites in 23 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Amstetten, Austria

  • Novartis Investigative Site

    Feldkirch, Austria

  • Novartis Investigative Site

    Hallein, Austria

  • Novartis Investigative Site

    Kirchdorf an der Krems, Austria

  • Novartis Investigative Site

    Leoben, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Perg, Austria

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Wels, Austria

  • Novartis Investigative Site

    Antwerp, Belgium

  • Novartis Investigative Site

    Balen, Belgium

  • Novartis Investigative Site

    Braine-l'Alleud, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Éghezée, Belgium

  • Novartis Investigative Site

    Erpent, Belgium

  • Novartis Investigative Site

    Geraardsbergen, Belgium

  • Novartis Investigative Site

    Gilly, Belgium

  • Novartis Investigative Site

    Halen, Belgium

  • Novartis Investigative Site

    Hasselt, Belgium

  • Novartis Investigative Site

    Heusy, Belgium

  • Novartis Investigative Site

    Ieper, Belgium

  • Novartis Investigative Site

    Knokke-Heist, Belgium

  • Novartis Investigative Site

    Lebbeke, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Maaseik, Belgium

  • Novartis Investigative Site

    Malmedy, Belgium

  • Novartis Investigative Site

    Mechelen, Belgium

  • Novartis Investigative Site

    Melsbroek, Belgium

  • Novartis Investigative Site

    Merksem, Belgium

  • Novartis Investigative Site

    Montegnée, Belgium

  • Novartis Investigative Site

    Natoye, Belgium

  • Novartis Investigative Site

    Paal-Beringen, Belgium

  • Novartis Investigative Site

    Ronse, Belgium

  • Novartis Investigative Site

    Saint-Médard, Belgium

  • Novartis Investigative Site

    Seraing, Belgium

  • Novartis Investigative Site

    Tournai, Belgium

  • Novartis Investigative Site

    Verviers, Belgium

  • Novartis Investigative Site

    Vilvoorde, Belgium

Showing 40 of 542 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.